Analyst Consensus ?
ConsensusBuy15 ratings
Bullish1280.0%
Neutral213.3%
Bearish16.7%
West Pharmaceutical Services, Inc. · WST · FY2025 Q4 · Calendar Q1 2026
West Pharma maintains 2026 outlook as HVP demand outpaces supply
The supplied analysis provides evidence for a constructive one-year operating outlook: management cited HVP, biologics, biosimilars and Annex 1 demand, maintained FY2026 growth guidance, and is expanding capacity while reducing capex. The thesis is not risk-free because supply constraints, oral GLP-1 substitution and regulatory or tariff exposure could limit delivery.
Reported Before market openNYSEHealthcare
$26.43B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.04
Consensus $1.83
EPS surprise
+11.5%
Reported versus consensus
Reported revenue
$805.0M
Consensus $794.9M
Revenue surprise
+1.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.0%
Event window
SPY move
-1.5%
Same window
Abnormal move
+0.5%
Stock minus SPY
Volume
1.7×
Versus trailing sessions
Subsequent drift
-3.3%
Up to 20 sessions
WSTSPY benchmark
Ask FN2 about WST FY2025 Q4
Transcript, numbers and history already loaded
Why did WST fall 1.0% after beating EPS estimates in FY2025 Q4?What changed in WST's guidance and outlook in FY2025 Q4?Give me the bull and bear case for WST after FY2025 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis shifts the focus from the prior quarter's guidance raise to maintained FY2026 guidance. It adds the planned mid-2026 SmartDose divestiture, lower 2026 capex, stronger free cash flow and evidence that HVP demand still exceeds supply.
Guidance delta
FY2026 guidance was maintained: 5%-7% organic revenue growth and approximately 10% EPS growth at the midpoint.
Key takeaways
- Management described 2025 net sales above $3 billion and organic growth above 4%, led by high-value product components.
- The FY2026 plan calls for 5%-7% organic revenue growth and approximately 10% EPS growth at the midpoint.
- Capacity expansions in Dublin and Grand Rapids are intended to address demand that currently exceeds supply.
- The SmartDose business sale is planned for mid-2026, with proceeds available for growth investment or shareholder returns.
- The company is reducing 2026 capex to $250-$275 million while emphasizing free cash flow and margin improvement.
Management priorities
- Expand HVP capacity and address supply constraints
- Advance West Synchrony pre-fillable syringes and drug-handling operations
- Complete the SmartDose divestiture
- Develop elastomer formulations and pursue growth opportunities
- Continue Annex 1 upgrade execution while reducing capex
Follow WST with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$376.63Current
$295Low
$369.14Average
$447High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Sep 22, 2026 |
| UBS | Buy | Buy | Maintain | Sep 9, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 3, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 2, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Jun 9, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2026 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Jefferies | Buy | Hold | Upgrade | Feb 7, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 14, 2022 |
| Bank of America | Underperform | Neutral | Downgrade | Dec 12, 2019 |
| William Blair | Outperform | Outperform | Maintain | Apr 23, 2019 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 24, 2018 |
| Wells Fargo | Outperform | Outperform | Maintain | Oct 27, 2017 |
| Janney Capital | Buy | Buy | Maintain | Jan 8, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $376.63. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Kallum Titchmarsh | $400 | $361.73 | +6.2% | Sep 22, 2026 |
| UBS | Analyst unavailable | $415 | $338.06 | +10.2% | Sep 9, 2026 |
| Evercore ISI | Analyst unavailable | $425 | $333.12 | +12.8% | Jul 27, 2026 |
| BNP Paribas | Analyst unavailable | $447 | $353.71 | +18.7% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $365 | $353.68 | -3.1% | Jul 9, 2026 |
| Evercore ISI | Daniel Markowitz | $410 | $359.27 | +8.9% | Jul 6, 2026 |
| KeyBanc | Analyst unavailable | $390 | $365 | +3.5% | Jul 2, 2026 |
| Barclays | Luke Sergott | $400 | $319.75 | +6.2% | Jun 9, 2026 |
| Morgan Stanley | Analyst unavailable | $315 | $306.39 | -16.4% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $310 | $306.16 | -17.7% | Apr 27, 2026 |
| UBS | Dan Leonard | $340 | $246.6 | -9.7% | Feb 13, 2026 |
| Deutsche Bank | Analyst unavailable | $315 | $247.49 | -16.4% | Feb 13, 2026 |
| Barclays | Luke Sergott | $265 | $243.61 | -29.6% | Feb 13, 2026 |
| Jefferies | David Windley | $295 | $249.97 | -21.7% | Feb 10, 2026 |
| Evercore ISI | Daniel Markowitz | $320 | $237.88 | -15.0% | Feb 3, 2026 |
| Morgan Stanley | Analyst unavailable | $285 | $274.14 | -24.3% | Dec 1, 2025 |
| Barclays | Analyst unavailable | $325 | $293.62 | -13.7% | Oct 27, 2025 |
| UBS | Dan Leonard | $355 | $307.25 | -5.7% | Oct 24, 2025 |
| Deutsche Bank | Justin Bowers | $345 | $304.74 | -8.4% | Oct 24, 2025 |
| Evercore ISI | Daniel Markowitz | $390 | $309.28 | +3.5% | Oct 23, 2025 |
| Evercore ISI | Analyst unavailable | $350 | $268.07 | -7.1% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $275 | $271.42 | -27.0% | Oct 2, 2025 |
| Redburn Partners | Jamie Clark | $311 | $257.53 | -17.4% | Sep 15, 2025 |
| Barclays | Luke Sergott | $245 | $222.68 | -34.9% | Jun 24, 2025 |
| Jefferies | David Windley | $393 | $287.85 | +4.3% | Nov 19, 2024 |
| Jefferies | David Windley | $536 | $413 | +42.3% | Feb 7, 2024 |
| Deutsche Bank | Analyst unavailable | $250 | $251.9 | -33.6% | Dec 14, 2022 |
| UBS | Analyst unavailable | $250 | $222.84 | -33.6% | Nov 30, 2022 |
Track every rating change on WST the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationWest Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies.…
Historical context
All WST earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
- SNXFY2026 Q3 · September 24, 2026+20.9% EPS-9.9% move
- DRIFY2027 Q1 · September 24, 20260.0% EPS-3.0% move
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
- GISFY2027 Q1 · September 23, 2026+4.6% EPS+1.0% move
Get the WST recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-09-29T21:11:00.992723+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-29T21:11:00.990549+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-29. For educational purposes only; not investment advice.